[fcb5af]: / literature / by_gene / MKI67.tsv

Download this file

# pmid doi year title Hugo_Symbol
1 35241462 10.1136/bmjopen-2020-041961 2022 Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis. MKI67
2 35248490 10.1016/j.clbc.2022.02.001 2022 Changes in Ki-67 in Residual Tumor and Outcome of Primary Inflammatory Breast Cancer Treated With Trimodality Therapy. MKI67
3 35393909 10.1080/09513590.2022.2061454 2022 Effects of clinical and metabolic variables and hormones on the expression of immune protein biomarkers in the endometrium of women with polycystic ovary syndrome and normal-cycling controls. MKI67
4 35583604 10.1158/1078-0432.CCR-21-3347 2022 Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL. MKI67
5 32873701 10.1136/jclinpath-2020-206956 2021 Improving precise counting of mitotic cells in mantle cell lymphoma using phosphohistone H3 (PHH3) antibody. MKI67
6 33136585 10.1097/PAS.0000000000001609 2021 Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. MKI67
7 33404293 10.1080/15548627.2020.1871204 2021 BNIP3L-mediated mitophagy is required for mitochondrial remodeling during the differentiation of optic nerve oligodendrocytes. MKI67
8 33723149 10.4103/jcrt.JCRT_311_19 2021 Role of WT1, B-cell lymphoma 2, Ki-67 (Mib1), and Her2/Neu as diagnostic and prognostic immunomarkers in ovarian serous and endometroid carcinoma. MKI67
9 33737021 10.1016/j.taap.2021.115491 2021 Pyrazole (1, 2-diazole) induce apoptosis in lymphoma cells by targeting BCL-2 and BCL-XL genes and mitigate murine solid tumour development by regulating cyclin-D1 and Ki-67 expression. MKI67
10 33788720 10.21873/anticanres.14886 2021 Tumor Cell Microenvironment and Microvessel Density Analysis in MALT Type Lymphoma. MKI67
11 33941102 10.1186/s12885-021-08142-7 2021 Normal and cancer fibroblasts differentially regulate TWIST1, TOX and cytokine gene expression in cutaneous T-cell lymphoma. MKI67
12 33991204 10.1007/s00277-021-04473-4 2021 Elevated expression of HMGB1 is prognostic of poor survival in patients with relapsed/refractory T/NK-CL. MKI67
13 34258959 10.7754/Clin.Lab.2021.201132 2021 Prognostic Values of MicroRNA-21 and Ki-67 in Diffuse Large B-Cell Lymphoma Patients: Egyptian Experience. MKI67
14 34339560 10.1111/pin.13148 2021 Diagnostic utility and prognostic significance of the Ki-67 labeling index in diffuse large B-cell lymphoma transformed from follicular lymphoma: a study of 76 patients. MKI67
15 34535585 10.1159/000518452 2021 Efficacy of the Antigenicity-Retaining Ability of Fixative Solutions for Liquid-Based Cytology: Immunocytochemistry of Long-Term Storage. MKI67
16 34898577 10.3390/curroncol28060383 2021 Evaluation of Ki-67 as a Prognostic Marker in Diffuse Large B-Cell Lymphoma-A Single-Center Retrospective Cohort Study. MKI67
17 31698053 10.1016/j.micpath.2019.103845 2020 Epigenetics evaluation of the oncogenic mechanisms of two closely related bovine and human deltaretroviruses: A system biology study. MKI67
18 32059385 10.3390/medicina56020072 2020 Bmi-1 Immunohistochemical Expression in Endometrial Carcinoma is Correlated with Prognostic Activity. MKI67
19 32443328 10.1097/MD.0000000000020140 2020 Clinicopathological characteristics of primary central nervous system lymphoma with low 18F-fludeoxyglucose uptake on brain positron emission tomography. MKI67
20 32556361 10.2340/00015555-3578 2020 Stage-dependent Increase in Expression of miR-155 and Ki-67 and Number of Tumour-associated Inflammatory Cells in Folliculotropic Mycosis Fungoides. MKI67
21 32727513 10.1186/s12885-020-07200-w 2020 Comprehensive analysis of spread through air spaces in lung adenocarcinoma and squamous cell carcinoma using the 8th edition AJCC/UICC staging system. MKI67
22 32767162 10.1007/s10637-020-00979-2 2020 Glioma progression is suppressed by Naringenin and APO2L combination therapy via the activation of apoptosis in vitro and in vivo. MKI67
23 32843697 10.1038/s41598-020-71058-y 2020 Activation-induced cytidine deaminase overexpression in double-hit lymphoma: potential target for novel anticancer therapy. MKI67
24 30224636 10.1038/s41401-018-0108-5 2019 CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression. MKI67
25 30328119 10.1111/cup.13375 2019 Utility of CD30, Ki-67, and p53 in assisting with the diagnosis of mycosis fungoides with large cell transformation. MKI67
26 30446982 10.1007/s10753-018-0930-4 2019 Breast Implant Texturization Does Not Affect the Crosstalk Between MSC and ALCL Cells. MKI67
27 30467824 10.14670/HH-18-067 2019 Next-generation sequencing-based characterization of the invasion by anatomical contiguity in a primary osseous diffuse large B-cell lymphoma. Correlation between the genetic profile of the malignancy and the clinical outcome of the patient. MKI67
28 30768440 10.1097/PAS.0000000000001233 2019 SOX11-negative Mantle Cell Lymphoma: Clinicopathologic and Prognostic Features of 75 Patients. MKI67
29 30964854 10.12659/MSM.914934 2019 The Signal Transducer and Activator of Transcription 5B (STAT5B) Gene Promotes Proliferation and Drug Resistance of Human Mantle Cell Lymphoma Cells by Activating the Akt Signaling Pathway. MKI67
30 31219818 10.1097/PAS.0000000000001312 2019 Mantle Cell Lymphoma Involving Skin: A Clinicopathologic Study of 37 Cases. MKI67
31 31259656 10.1080/10428194.2019.1633629 2019 The contribution of MYC and PLK1 expression to proliferative capacity in diffuse large B-cell lymphoma. MKI67
32 31492883 10.1038/s41598-019-49326-3 2019 Classification of aggressive and classic mantle cell lymphomas using synchrotron Fourier Transform Infrared microspectroscopy. MKI67
33 27490760 10.1097/PAI.0000000000000424 2018 Prognostic Significance of High Ki-67 Index and Histogenetic Subclassification in Primary Central Nervous System Lymphoma. MKI67
34 28868942 10.1080/10428194.2017.1370547 2018 MYC immunohistochemical and cytogenetic analysis are required for identification of clinically relevant aggressive B cell lymphoma subtypes. MKI67
35 29196411 10.1182/blood-2017-07-797019 2018 Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. MKI67
36 29319177 10.1111/cei.13099 2018 Characterization of ectopic lymphoid structures in different types of acute renal allograft rejection. MKI67
37 29579328 10.1002/cncr.31328 2018 Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. MKI67
38 29785709 10.1111/bjh.15411 2018 Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). MKI67
39 30272319 10.3892/or.2018.6743 2018 Effects of 60 kDa prolactin and estradiol on metabolism and cell survival in cervical cancer: Co‑expression of their hormonal receptors during cancer progression. MKI67
40 30385732 10.1172/jci.insight.120974 2018 Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. MKI67
41 28270020 10.1080/10428194.2017.1298754 2017 18F-FDG PET/CT and extragastric MALT lymphoma: role of Ki-67 score and plasmacytic differentiation. MKI67
42 26272457 10.1111/his.12808 2016 Analysis of NSCLC tumour heterogeneity, proliferative and 18F-FDG PET indices reveals Ki67 prognostic role in adenocarcinomas. MKI67
43 26926679 10.1200/JCO.2015.63.8387 2016 Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. MKI67
44 27959929 10.1371/journal.pmed.1002197 2016 Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study. MKI67
45 25381338 10.1158/1078-0432.CCR-14-1913 2015 Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer. MKI67
46 25431344 10.1111/his.12624 2015 Computerized image analysis of the Ki-67 proliferation index in mantle cell lymphoma. MKI67
47 25504496 10.1007/s12185-014-1719-3 2015 High Ki-67 expression in involved bone marrow predicts worse clinical outcome in diffuse large B cell lymphoma patients treated with R-CHOP therapy. MKI67
48 25573205 10.3109/10428194.2015.1004169 2015 Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients. MKI67
49 25648135 10.1007/s10549-015-3288-4 2015 Bcl2 and Ki67 refine prognostication in luminal breast cancers. MKI67
50 25712457 10.1093/annonc/mdv074 2015 Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL). MKI67
51 26107196 10.7314/apjcp.2015.16.11.4515 2015 Ki-67 Can Predict the Response to the Gemcitabine, Oxaliplatin And L-asparaginase Regimen (GELOX) and Prognosis in Patients with Nasal Natural Killer/T-cell Lymphoma. MKI67
52 26546525 2015 Suppression of BCL2 by Antisense Oligonucleotides and Compensation by Non-Targeted Genes May Enhance Tumor Proliferation. MKI67
53 24013721 10.1038/cdd.2013.123 2014 The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma. MKI67
54 24597851 10.1186/1471-2407-14-153 2014 Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis. MKI67
55 24684350 10.1111/bjh.12854 2014 SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study. MKI67
56 25204411 10.1007/s12032-014-0218-y 2014 Prognostic significance of Ki-67 antigen expression in extranodal natural killer/T-cell lymphoma, nasal type. MKI67
57 25374203 10.7314/apjcp.2014.15.20.8759 2014 Distribution of Ki67 proliferative indices among WHO subtypes of non-Hodgkin's lymphoma: association with other clinical parameters. MKI67
58 23240716 10.1111/his.12009 2013 Variability in morphology and cell proliferation in sequential biopsies of mantle cell lymphoma at diagnosis and relapse: clinical correlation and insights into disease progression. MKI67
59 24471040 10.5125/jkaoms.2013.39.4.182 2013 Expansile keratocystic odontogenic tumor in the maxilla: immunohistochemical studies and review of literature. MKI67
60 22531522 10.4103/0973-1482.95182 2012 Correlation of fluorodeoxyglucose uptake and tumor-proliferating antigen Ki-67 in lymphomas. MKI67
61 21738398 2011 Expression of cell proliferation and apoptosis biomarkers in pterygia and normal conjunctiva. MKI67
62 20038236 10.3109/10428190903440953 2010 SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma. MKI67
63 20181625 2010 Molecular profiling using tissue microarrays as a tool to identify predictive biomarkers in laryngeal cancer treated with radiotherapy. MKI67
64 20369488 2010 [Expression and significance of P53 and P21 in nasal NK/T-cell lymphoma]. MKI67
65 20530581 10.1158/1541-7786.MCR-10-0131 2010 PRDM1 is required for mantle cell lymphoma response to bortezomib. MKI67
66 20882047 10.1038/leu.2010.221 2010 COX-2 is a novel target in therapy of mycosis fungoides. MKI67
67 18778369 10.1111/j.1600-0609.2008.01152.x 2009 Expression levels of apoptosis-related proteins and Ki-67 in nasal NK / T-cell lymphoma. MKI67
68 19452712 2009 [Expressions of p53 and p21 in nasal NK/T-cell lymphoma and their relationship with the proliferation and apoptosis of cells]. MKI67
69 20001925 10.2174/092986609789353646 2009 Proteomic analysis of mitochondria in Raji cells following exposure to radiation: implications for radiotherapy response. MKI67
70 18077791 10.1182/blood-2007-10-117010 2008 Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. MKI67
71 18612102 10.1182/blood-2008-03-145128 2008 A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). MKI67
72 18766962 10.1080/10428190802140055 2008 Low rather than high Ki-67 protein expression is an adverse prognostic factor in diffuse large B-cell lymphoma. MKI67
73 17296585 10.3324/haematol.10682 2007 MUM1 expression dichotomises follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes. MKI67
74 17693651 10.1093/annonc/mdm183 2007 Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. MKI67
75 16623776 10.1111/j.1365-2559.2006.02378.x 2006 Ki67 staining pattern as a diagnostic tool in the evaluation of lymphoproliferative disorders. MKI67
76 17225522 2006 [Expression and its significance of STAT3, STAT5, Survivin and Ki67 in nasal NK/T cell lymphoma]. MKI67
77 15931389 10.1172/JCI23412 2005 Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. MKI67
78 16295759 2005 [Expression of proliferation marker Ki 67 in chronic lymphocytic leukemia]. MKI67